Pfizer recalls select lots of Accuretic quinapril HCl/hydrochlorothiazide tablets, quinapril/hydrochlorothiazide tablets, and quinapril HCl/hydrochlorothiazide tablets due to N-nitroso- quinapril content; products sold in US, Puerto Rico from 2019 to 2022

Sample article from our Health Care Sector

NEW YORK, New York , March 22, 2022 (press release) –

Pfizer is voluntarily recalling Accuretic (quinapril HCl/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake (ADI) level. Pfizer will recall six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.

 

 

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.i

These products are indicated for the treatment of hypertension. Lowering blood pressure reduces the risk of fatal  and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ii The products have a safety profile that has been established over 20 years of marketing authorization and through a robust clinical program. To date, Pfizer is not aware of reports of adverse events that have been assessed to be related to this recall. Pfizer believes the benefit/risk profile of the products remains positive based on currently available data. Although long- term ingestion of N-nitroso-quinapril may be associated with a potential increased cancer risk in humans, there is no immediate risk to patients taking this medication. Patients currently taking the products should consult with their doctor about alternative treatment options.

The NDC, Lot Number, Expiration Date, and Configuration details for these products are indicated in the tables below and photos of the products can be found at the end of this press release. The product lots were distributed nationwide to wholesalers and Distributors in the United States and Puerto Rico from November 2019 to March 2022.

Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 10/12.5 mg
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/12.5 mg
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/25 mg

NDC Lot Number Expiration Date Strength Configuration/Count
0071-3112-23 FG5379 08/2024 10/12.5 mg 1 x 90 count bottle
0071-0222-23 EA6686 04/2022 10/12.5 mg 1 x 90 count bottle
0071-5212-23 FG5381 08/2024 20/12.5 mg 1 x 90 count bottle
0071-0220-23 EA6665 04/2022 20/12.5 mg 1 x 90 count bottle
0071-0220-23 CN0640 04/2022 20/12.5 mg 1 x 90 count bottle
0071-0223-23 ET6974 02/2023 20/25 mg 1 x 90 count bottle


quinapril and hydrochlorothiazide tablets, 20/25 mg
quinapril HCl/hydrochlorothiazide tablets, 20/12.5 mg
quinapril HCl/hydrochlorothiazide tablets, 20/25 mg

NDC Lot Number Expiration Date Strength Configuration/Count
59762-5225-9 FE3714 02/2023 20/25 mg 1 x 90 count bottle
59762-0220-1 DN6931 03/2023 20/12.5 mg 1 x 90 count bottle
59762-0220-1 ED3904 03/2023 20/12.5 mg 1 x 90 count bottle
59762-0220-1 ED3905 03/2023 20/12.5 mg 1 x 90 count bottle
59762-0223-1 DP3414 02/2023 20/25 mg 1 x 90 count bottle


Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified direct consignees by letter to arrange for return of any recalled product.

Wholesalers and distributors with an existing inventory of the lots, listed in the table above, should stop use and distribution and quarantine the product immediately.

If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request they immediately cease distribution of the affected product and promptly contact Sedgwick at 888-843-0247 (Mon.-Fri. 8:00 am - 5:00 pm ET) to obtain a Business Reply Card (BRC) to initiate the return process.

Patients who are taking this product should consult with their healthcare provider or pharmacy to determine if they have the affected product. Patients with the affected product should contact Sedgwick at 888-843-0247 (Mon.-Fri. 8:00 am - 5:00 pm ET) for instructions on how to return their product and obtain reimbursement for their cost.

Healthcare Professionals with questions regarding this recall can contact Pfizer using the below information.

Contact Center Contact Information Area of Support
Pfizer Medical Information

Pfizer Drug Safety
800-438-1985, option 3
(Mon.- Fri. 8 am-9 pm ET)
800-438-1985, option 1
For medical questions regarding the product

To report adverse events and product complaints


Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800- FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

References:
i  https://www.fda.gov/drugs/drug-safety-andavailability/information-about-nitrosamine-impurities-medications
ii  William B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:30213104. doi:10.1093/eurheartj/ehy339.

Appendix A: Product Photos

Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets

 

 

 

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.